Bcl-2 Inhibitor Compounds Modulating Apoptosis via Structural Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Bcl-2 inhibitors for treating hyper-proliferative diseases like cancer and inflammation face challenges due to short half-life and toxicity issues, necessitating the development of compounds with improved potency, stability, selectivity, and pharmacokinetic properties.
Innovation Solution
Development of novel compounds of formula (I) and their pharmaceutically acceptable salts, which inhibit anti-apoptotic Bcl-2 family proteins, offering enhanced therapeutic benefits for treating hyper-proliferative diseases by modulating Bcl-2 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing Bcl-2 inhibitors are used to treat hyper-proliferative diseases, then therapeutic effect is achieved, but short half-life and toxicity issues occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of Bcl-2 inhibitors through various substituent groups (R1, RX, RE8, L1, L2, Q2, Q3) to optimize pharmacokinetic properties. Specifically, the invention changes molecular parameters such as lipophilicity, molecular weight, and structural rigidity to extend half-life while maintaining therapeutic efficacy against hyper-proliferative diseases
2Reliability
If existing Bcl-2 inhibitors are used to treat hyper-proliferative diseases, then therapeutic effect is achieved, but toxicity issues occur
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups at particular positions on the core molecular structure. Different substituents (R1 at position 1, RX at position 3, RE8 at position 8) are strategically placed to enhance target selectivity for Bcl-2 proteins while reducing off-target toxicity. This localized modification approach allows optimization of the therapeutic index by improving potency against cancer cells while sparing normal tissues
Solution Approach 2:
The patent changes molecular parameters including lipophilicity, hydrogen bonding capacity, and molecular size to reduce toxicity. By adjusting these parameters through systematic substitution patterns, the invention achieves better selectivity for pathological Bcl-2 overexpression in cancer while minimizing adverse effects on normal physiological processes
3Reliability
If novel compounds of formula (I) are developed to improve potency and stability, then therapeutic benefits are enhanced, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecule into distinct functional modules: a core structure and separate substituent groups (R1, RX, RE8, L1, L2, Q2, Q3). This modular approach allows systematic optimization of potency and stability through controlled variation of individual segments while maintaining overall structural organization. The segmented design facilitates rational drug design and simplifies structure-activity relationship analysis despite increased molecular complexity
Data Source
AI summary
Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.